Aneurysmal subarachnoid haemorrhage—cerebral vasospasm and prophylactic ibuprofen: a randomised controlled pilot trial protocol

Mojtaba Dayyani, Ermia Mousavi Mohammadi, Vahid Ashoorion, Behnam Sadeghirad, Mohammadreza Javedani Yekta, James C Grotta, Nestor R Gonzalez, Samira Zabihyan

ABSTRACT

Introduction Cerebral vasospasm (CVS) is the leading cause of mortality and morbidity following aneurysmal subarachnoid haemorrhage (aSAH). One of the recently implicated underlying mechanisms of CVS is inflammatory cascades. Specific feasibility objectives include determining the ability to recruit 30 participants over 24 months while at least 75% of them comply with at least 75% of the study protocol and being able to follow 85% of them for 3 months after discharge.

Methods and analysis This is a feasibility study for a randomised controlled trial. Eligible participants are adult patients who are 18 years of age and older with an aSAH confirmed by a brain CT scan, and CT angiography, or magnetic resonance angiography, or digital subtraction angiography who admitted to the emergency department within 12 hours of the ictus. Eligible subjects will be randomised 1:1 for the administration of either ibuprofen or a placebo, while both groups will concomitantly be treated by the standard of care for 2 weeks. Care givers, patients, outcome assessors and data analysts will be blinded. This will be the first study to investigate the preventive effects of a short-acting non-steroidal anti-inflammatory drug on CVS and the key expected outcome of this pilot study is the feasibility and safety assessment of the administration of ibuprofen in patients with aSAH. The objectives of the definitive trial would be to assess the effect of ibuprofen relative to placebo on mortality, CVS, delayed cerebral ischaemia, and level of disability at 3-month follow-up.

Ethics and dissemination This study is approved by Mashhad University of Medical Sciences ethical committee (IR.MUMS.MEDICAL.REC.1398.225). Results from the study will be submitted for publication regardless of whether or not there are significant findings.

Trial registration number ISRCTN14611625.

INTRODUCTION

Background and rationale

Aneurysmal subarachnoid haemorrhage (aSAH) accounts for 5%–10% of all strokes worldwide, which approximately equals to a total of 600 000 new cases per year. Up to 44% of such cases will die, and almost 20% of the survived ones would become disabled and dependent. Cerebral vasospasm (CVS) following aSAH is the leading cause of mortality and morbidity. The exact mechanisms of the complex inflammatory cascade leading to CVS is not well understood, and usual treatments have no sufficient therapeutic effects. However, several studies support the hypothesis that local and systemic inflammatory responses may participate in the process of CVS and its consequent poor outcomes. Increased plasma and cerebrospinal fluid level of inflammatory markers, like tumour necrosis factor-α, and various interleukins during SAH is seen, and this increment is correlated with poor neurological outcomes. Moreover, the systemic inflammatory response syndrome...
SIRS) is associated with poor outcomes after SAH and is presented in up to 63% of patients after SAH. This becomes an impetus to evaluate the possible effectiveness of anti-inflammatory medications after SAH.

Ibuprofen is one of the non-steroidal anti-inflammatory drugs (NSAIDs) which inhibit cyclooxygenase enzymes in a non-specific manner. In addition to decreasing the level of cytokines and prostaglandins, this drug also prevents the expression of two specific cell adhesion molecules, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 that belongs to the immunoglobulin superfamily. The immunoglobulin superfamily proteins are upregulated in patients who develop clinical vasospasm. Leucocyte integrins bind to these proteins on endothelial cells. The immunoglobulin superfamily proteins are necessary for leukocyte-endothelial cell adhesion and leucocyte migration (figure 1, online supplemental digital content, part 1).

Ibuprofen prevents inflammatory reactions caused by leucocytes with disrupting the process of migration. Ibuprofen’s efficacy on CVS has been proven in an intracranial model of rabbits when its intracranial administration initiated within 6 hours after SAH, but no effect was observed when treatment is begun later than 12 hours. As the acute phase of inflammation starts 3–4 hours after the SAH, ibuprofen is a fast-acting NSAID; it could prevent from binding of macrophages and neutrophils to the endothelial cells and entering the subarachnoid space; hence, reducing the intensity of acute phase inflammation. This inhibitory action, will decrease the number of trapped leucocytes dying and degranulating in the subarachnoid space in the next 2–4 days, and subsequently may reduce or prevent chronic vasospasm in the upcoming days of admission. Thus, the early administration of ibuprofen considered in this study might be a key to shut off the inflammatory cascade at the initial step (figure 1). Furthermore, in terms of side effects, the potential of NSAIDs to induce haemorrhagic stroke has been heavily dismissed by self-reports, prescriptions databases and large multicentred studies.

To date, we have found four clinical trials evaluating the efficacy of NSAIDs on vasospasm after aSAH, three of which were focused on the antiplatelet mechanism of aspirin. The fourth study was a placebo-controlled trial that assessed the preventive effects of meloxicam during 7 days after aSAH. However, no clinical data are available regarding the efficacy of a fast-acting oral NSAID for the administration in a narrow time interval.
after the occurrence of aSAH. In the current study, we sought to investigate the preventive role of ibuprofen on the CVS secondary to aSAH and its outcomes.

**Objectives**

The objective of the current pilot trial is to establish the feasibility of a larger trial by successfully recruiting 30 participants over a 24-month period and demonstrating adherence to our study protocol. Additionally, we will identify possible adverse events related to the administration of ibuprofen and determine whether its administration is superior to the standard treatment in terms of the prevention of CVS secondary to aSAH and its clinical outcomes.

**Trial design**

This pilot trial is a single centre, parallel randomised 1:1, controlled, clinical trial. Healthcare providers (physicians, intensive care unit (ICU) nurses, residents), patients, outcome assessors and data analysts will be blinded to treatment allocation. We followed Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist to conduct this pilot clinical trial protocol.

**METHODS**

**Subjects**

**Inclusion criteria**

1. Adult patients who are 18 years of age and older with an aSAH confirmed by a brain CT scan, and CT angiography, or magnetic resonance angiography, or digital subtraction angiography (figure 2).
2. Admitted to the emergency department within 12 hours of the ictus.
3. Patients must have a World Federation of Neurological Surgeons score of I, II or III at the initial examination.

**Exclusion criteria**

1. Patients who have hypersensitivity to aspirin, ibuprofen or other NSAIDs.
2. Previous and prolonged use of any type of NSAIDs.
3. History of aneurysmal re-bleeding, active bleeding of a gastrointestinal ulcer, haemodynamic instability, pregnancy, and current consumption of antiplatelet agents such as clopidogrel and aspirin.
4. Patients with history of myocardial infarction or percutaneous coronary interventions.

**Outcome measures and follow-up**

The goal of the current pilot trial is to establish the feasibility of a larger trial by successfully recruiting 30 participants over a 24-month period and demonstrating adherence to our study protocol. Based on the effect estimates coming out of this pilot study, we will calculate a proper sample size for the definitive trial. Specific feasibility objectives include determining:

1. Our ability to recruit 30 participants over 24 months.
2. Our ability to follow 85% of participants for 3 months.
3. Whether at least 75% of participants comply with at least 75% of the study protocol.

**Objectives for the definitive trial**

The primary research objective is:

To determine the effects of ibuprofen versus placebo on the rate of all-cause mortality.

The secondary research objectives are:

1. To assess whether the administration of ibuprofen in patients with aSAH, could prevent the occurrence of CVS vs placebo.
2. To determine the effects of ibuprofen versus placebo on the occurrence of delayed cerebral ischaemia (DCI).
3. To elucidate the effects of ibuprofen versus placebo on the level of disability based on modified Rankin Scale at discharge and 3-month follow-up.
Study description

The patients will be hospitalised for at least 14 days because the maximum inflammation in the subarachnoid space occurs between days 9 and 14. Based on our institutional protocol for the management of SAH, nimodipine 60 mg every 4 hours for 21 days, appropriate fluid therapy and phenytoin will be administered for all patients, and microsurgical aneurysmal clipping in patients presenting with large (>50 mL) intraparenchymal haematomas and middle cerebral artery aneurysms, or interventional coiling will be performed for elderly (>70 years of age) patients, in those presenting with poor-grade aSAH, and in those with aneurysms of the basilar apex. In the ibuprofen arm, eligible patients (online supplemental digital content, part 2) will receive ibuprofen capsules 400 mg/every 6 hours for 14 days, added to standard treatment (figure 3). Manufactured ibuprofen capsules will be administered orally in the intervention group. This dosage is an anti-inflammatory dose of ibuprofen and is placed in the middle of the therapeutic window of this drug. In the control group, placebo capsules that are manufactured identical to the ibuprofen capsules in terms of colour, size and shape; will be ordered in the same way as the intervention group. In subjects who are lethargic or have impaired consciousness, medication and placebo will be administered through enteral tube. The criteria for the evaluation of vasospasm and the scales used for assessing disability are discussed in online supplemental digital content, part 3.

Randomisation and allocation

To protect the blinding and integrity of the study (online supplemental digital content, part 4), a statistician who is not affiliated to the research team develops the randomisation plan. The statistician will generate a permuted block randomisation table using an online random sequence generator with an allocation list in random order. The allocation ratio is 1:1. An independent investigator allocates participants into two groups. The statistician who is not affiliated to the research team develops an online computer-based randomisation programme (http://www.randomization.com) to randomise patients. In the first step, the statistician uses Randomization.com’s pseudo-random number generator of Wichmann and Hill (1982) as modified by McLeod to specify a treatment (A or B) to each participant file numbered 1–30. In the second step, an independent investigator will provide a random permutation of all of the integers from the smallest to the largest by the programme. The independent investigator gives a file to each participant by the order provided in the previous step. The statistician will pick up a covered, sealed envelope from a box in which sequentially numbered envelopes are shuffled. Patients will receive drug A or B according to the method of allocation mentioned above.

Sample size

Our sample size is based on the confidence interval (CI) around the proportion of complete follow-up. We will consider the pilot successful if we achieved at least 85% follow-up at 3 months for our primary trial outcomes. If 29/30 participants achieve successful follow-up, the lower boundary of the 95% CI will be above 85%, and we will consider the trial feasible. If less than 22/30 achieve complete follow-up, the upper boundary of the CI will be below 85%, and we will consider the trial unfeasible. Therefore, if between 22 and 29 out of 30 patients complete a 3-month follow-up, the feasibility of the trial will remain uncertain; however, we will consider this satisfactory.

Figure 3 Timeline of the study. aSAH, aneurysmal subarachnoid haemorrhage; CTA, CT angiography; DSA, digital subtraction angiography; MRA, magnetic resonance angiography; mRS, modified Rankin Scale; q6h, every 6 hours; TCD, transcranial Doppler; WFNS, World Federation of Neurological Surgeons.
Data management and statistical analysis
The analysis and reporting of results will follow the Consolidated Standards of Reporting Trials (CONSORT) guidelines for reporting of randomised pilot and feasibility trials. Data will be collected on forms and archived in a password-protected encrypted electronic database. All recruited and randomised patients will be included in the analysis. Data analysis will be performed by a blinded investigator with treatment groups coded as A and B. All data collected will be summarised for reporting purposes using descriptive statistics.

Feasibility analysis (primary)
Data will be collected on forms and archived in a password-protected encrypted electronic database. Point estimates of recruitment and feasibility events, including adherence to protocol and follow-up rate at 3 months, will be presented as proportions with 95% CIs. The pilot study results will be evaluated to identify recruitment issues, data management issues and inform anticipated follow-up rates.

Efficacy analysis for definitive study (secondary)
We plan to include the data from our pilot in the definitive trial if we can demonstrate feasibility, assuming no important changes to our patient population, intervention or outcome measures. All patients enrolled in the trial and randomised will be included in the analysis, regardless of the level of adherence to the intervention or any other deviation from the protocol. Due to the low power of the pilot study, we will report the descriptive results for all efficacy-related and harm-related outcomes. We will not complete any subgroup, sensitivity or interim analysis due to the small sample size.

Quality assurance
The principal investigator along with a member of institutional ethics committee will systematically monitor and evaluate the various aspects of project to ensure standards of quality are met. Standards of quality include Good Clinical Practice Guidelines, Ethical Conduct for Research, study protocol and institutional policies. All investigators will participate in a training session before the commencement of the study to ensure the consistency of data collection and study procedures. Data will be managed in a secured computer system by a dedicated neurosurgery resident under the supervision of the principal investigator. In case of any doubt or uncertainty about data forms, the site investigators will be informed.

Also, for further assurance, multiple checkpoints are defined during the trial, including the presence of signed informed consents obtained by the neurosurgery residents, respect of the inclusion and exclusion criteria, appropriate and instant reporting of any adverse events and the monitoring of all steps of the follow-up. All the files and data will be sealed and archived in a secure place at the end of the trial, once the final analysis is completed.

Trial status
The trial is in the recruitment phase and patient enrolment is planned to be completed in April 2022, and the last recruited patient will be due for final outcome assessment in July 2022.

Safety considerations
Concerning complications of NSAIDs, patients are classified into three categories: low, moderate and high risk. Low-risk patients are those younger than 65 years without any cardiovascular risk factors. Moderate-risk patients are those 65 years of age or older without a history of gastrointestinal ulcer and who have a history of cardiovascular risk factors. Patients who are over 65 years of age or older with a history of gastrointestinal ulcer or multiple gastrointestinal risk factors, history of cardiovascular diseases, as well as having a history of heart failure are considered as a high-risk patient. In the first group, routine care will be provided. Pantoprazole is administered in the moderate-risk and high-risk group along with ibuprofen. We strictly monitor blood pressure as a part of our routine management of all patients in ICU. Moreover, urea, creatinine and electrolytes (sodium and potassium) of moderate-risk patients will be measured every 3 days, while the same tests will be requested for the high-risk group every day. Administration of the study drug ceases if any serious adverse events happen or adverse effects prevent the tolerability of the ibuprofen (online supplemental digital content, parts 5 and 6) or the patient wishes to withdraw the consent before the study ends.

Based on the recommendation of extension of the CONSORT statement on better reporting of harms in randomised trials,27 29 we will collect and appropriately report all good and bad events and outcomes so that they may be compared across treatment groups. Also, according to the same statement, the balance of benefits and harm will be discussed in the final publication of the pilot trial. In addition, for assessing the severity of adverse events (including clinical and laboratory abnormalities) and grading them among the participants, we will use the Table for Grading the Severity of Adult and Pediatric Adverse Events.30 Four comprehensive sections regarding the management and reporting adverse events are provided in the online supplemental digital content, parts 5, 6, 7 and 8.

Follow-up
The clinical team will do in person follow-up with the patients every day for any adverse events during initial admission and weekly for the first 3 weeks if discharged. A 3-month in-person visit or phone interview is arranged for the assessment of disability outcomes and possible adverse events. Contact information will be available for the enrolled patients for questions or possible adverse event reports during the study period.

Expected outcomes of the study
The key expected result of this pilot study is the feasibility and safety assessment of the administration of ibuprofen in patients with aSAH. The objectives of the definitive
trial are mentioned in the methods section. During the pilot trial, we will collect information on all outcomes for the definitive trial.

**Duration of the project**
This project is scheduled to last 24 months. The first patient recruited in June 2020 and the last one is planned to be included by April 2022, the end of the follow-up period for the last patient would be in July 2022.

**Project management**
Principal investigator: Oversight of all study procedures and managing the relations with the source of funding.

Research scientist: Study design, drafting of the proposal, randomised controlled trial registration and drafting of the manuscript.

Study coordinator: Blinding, randomisation of the participants, organising datasheets and coordinating members of the team.

Neurosurgery residents: Check patients’ eligibility, consenting, assessing clinical DCI, diagnosing and managing of the adverse events, order Transcranial Doppler (TCD), and ibuprofen.

Neurologist: A clinical stroke fellow will do the TCD.

Statistician: Assistance regarding study design, revising the manuscript and data analysis.

**Ethics and dissemination**
This study is approved by Mashhad University of Medical Sciences (MUMS) ethical committee (IR.MUMS.MEDICAL.REC.1398.225). Written informed consent will be obtained from the eligible patients or next of kin for enrollment to the study.

**Dissemination policy**
Results from the study will be submitted for publication regardless of whether or not there are significant findings. Every attempt will be made to ensure that the amount of time between completing data collection and the release of study findings is minimised. The Methods Centre will also be responsible for reporting required results on the ISRCTN registry.

**Patient and public involvement**
Patients and public were not involved in this study.

**DISCUSSION**
CVS is a common devastating complication of the aSAH. Pharmacological management of this clinical problem is still a controversial issue.

We have found some pieces of evidence through in vitro,\(^31\) animal\(^32\) and human\(^33,34\) studies indicating that some NSAIDs might be a promising choice to be used as a repurposing approved agent for the prevention of CVS secondary to aSAH.

In a propensity score-matched analysis study by Nassiri et al.,\(^35\) consumption of NSAIDs with various therapeutic indications was assessed in patients with aSAH. Results demonstrated a reduction in mortality and improved functional outcomes.\(^24\) These effects were independent of the development of DCI or vasospasm. Furthermore, patients treated with NSAIDs had reduced ICU and hospital stay. The authors hypothesised that inflammation may have a critical role in development of poor outcomes (disability and death) after aSAH and patients with aSAH may find some benefit from NSAIDs.

A large, high-quality trial is needed to establish whether adding ibuprofen to standard treatment effectively reduces vasospasm after aSAH. Such a trial poses fundamental challenges for methodological design as well as complexities of execution. Thus, a prerequisite pilot trial is required to justify if the preliminary plan can be implemented in a larger definitive trial.

Ibuprofen is a Food and Drug Administration-approved anti-inflammatory medication; however, using it in a new clinical condition as a repurposing approved agent to prevent CVS requires further evaluation. Since there is no previous phase III trial for this purpose, we planned to run feasibility pilot study before the definitive trial.

**Author affiliations**
1Division of Neurosurgery, City of Hope Beckman Research Institute and Medical Center, Duarte, California, USA
2Department of Neurosurgery, Mashhad University of Medical Sciences, Mashhad, Razavi Khorasan, Iran
3Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
4Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada
5Mobile Stroke Unit and Stroke Research Program, Memorial Hermann Texas Medical Center, Houston, Texas, USA
6Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA

**Acknowledgements**
We appreciate the deputy of research at Mashhad University of Medical Sciences for the financial support of this project.

**Contributors**
SZ and MD conceptualised the study. MD, EMM, VA and BS designed the study, EMM and MJY coordinated the administrative tasks. EMM and MD did the literature search, and drafted the initial version of the manuscript. MD designed the concept map and all figures. JG, NG and SZ and all authors critically reviewed and approved the final manuscript as submitted.

**Funding**
This study was funded by Mashhad University of Medical Sciences, Deputy of Research, Grant No.971587.

**Competing interests**
None declared.

**Patient and public involvement**
Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication**
Not applicable.

**Provenance and peer review**
Not commissioned; externally peer reviewed.

**Supplemental material**
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access**
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is
REFERENCES

1. Feigin VL, Lawes CMM, Bennett DA, et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. *Lancet Neurol* 2008;7:331-43.

2. Mocco J, Morgenstern LB, Sereby S, et al. Clinical practice guideline for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association. *J Neurosurg* 2015;123(1 Suppl):S1-19.

3. Feigin VL, Lawes CMM, Bennett DA, et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. *Lancet Neurol* 2008;7:331-43.

4. Mocco J, Morgenstern LB, Sereby S, et al. Clinical practice guideline for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association. *J Neurosurg* 2015;123(1 Suppl):S1-19.

5. Feigin VL, Lawes CMM, Bennett DA, et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. *Lancet Neurol* 2008;7:331-43.

6. Mocco J, Morgenstern LB, Sereby S, et al. Clinical practice guideline for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association. *J Neurosurg* 2015;123(1 Suppl):S1-19.
Supplemental digital content (SDC)

Prophylactic effects of Ibuprofen on cerebral vasospasm following aneurysmal subarachnoid hemorrhage: Protocol for a randomised placebo-controlled pilot trial

Authors:
Mojtaba Dayyani1,2 Ermia Mousavi Mohammadi2, Vahid Ashoorion3, Behnam Sadeghirad3, Mohammadreza javedani yekta1, James Grotta4, Nestor Gonzalez5, Samira Zabihyan2,*

Table of Contents

SDC, part 1. REFERENCES OF THE CONCEPT MAP 2
SDC, part 2. ENROLMENT 3
SDC, part 3. CRITERIA FOR THE EVALUATION OF VASOSPASM AND DISABILITY 4
SDC, part 4. BLINDING 4
SDC, part 5. ADVERSE EVENTS DEFINITION 5
SDC, part 6. SERIOUS ADVERSE EVENTS 5
SDC, part 7. ADVERSE EVENT (AE) REPORTING 7
SDC, part 8. REFERENCES FOR SUPPLEMENTARY TEXT 7
SDC, part 1. References of the concept map

1. Chaichana KL, Pradilla G, Huang J, et al. Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage. *World neurosurgery* 2010;73(1):22-41. doi: 10.1016/j.surneu.2009.05.027 [published Online First: 2010/05/11]

2. van den Bergh WM, Algra A, Dorhout Mees SM, et al. Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH Study. *Stroke* 2006;37(9):2326-30. doi: 10.1161/01.STR.0000236841.16055.0f [published Online First: 2006/08/05]

3. Frazier JL, Pradilla G, Wang PP, et al. Inhibition of cerebral vasospasm by intracranial delivery of ibuprofen from a controlled-release polymer in a rabbit model of subarachnoid hemorrhage. *Journal of neurosurgery* 2004;101(1):93-8. doi: 10.3171/jns.2004.101.1.0093 [published Online First: 2004/07/17]

4. Chyatte D. Prevention of chronic cerebral vasospasm in dogs with ibuprofen and high-dose methylprednisolone. *Stroke* 1989;20(8):1021-26.

5. Kobayashi H, Hayashi M, Kobayashi S, et al. Cerebral vasospasm and vasoconstriction caused by endothelin. *Neurosurgery* 1991;28(5):673-79.

6. Edwards DH, Byrne JV, Griffith TM. The effect of chronic subarachnoid hemorrhage on basal endothelium-derived relaxing factor activity in intrathecal cerebral arteries. *Journal of neurosurgery* 1992;76(5):830-37.

7. Sabri M, Ai J, Lakovic K, et al. Mechanisms of microthrombi formation after experimental subarachnoid hemorrhage. *Neuroscience* 2012;224:26-37.

8. Westermaier T, Stetter C, Kunze E, et al. Controlled hypercapnia enhances cerebral blood flow and brain tissue oxygenation after aneurysmal subarachnoid hemorrhage: results of a phase 1 study. *Neurocritical care* 2016;25(2):205-14.

9. Tani E. Molecular mechanisms involved in development of cerebral vasospasm. *Neurosurgical focus* 2002;12(3):1-8.

10. Chrissobolis S, Sobey CG. Recent evidence for an involvement of rho-kinase in cerebral vascular disease. *Stroke* 2006;37(8):2174-80.

11. Macdonald R. Pathophysiology and molecular genetics of vasospasm. Cerebral Vasospasm: Springer 2001:7-11.

12. Laher I, Zhang JH. Protein kinase C and cerebral vasospasm. *Journal of Cerebral Blood Flow & Metabolism* 2001;21(8):887-906.

13. Kolias AG, Sen J, Belli A. Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches. *Journal of neuroscience research* 2009;87(1):1-11.
SDC, part 2. Enrolment

Patient screening for eligibility and recruitment will be conducted at Ghaem Teaching Hospital, Mashhad, Iran. Two neurosurgery residents will first visit the patients and check the eligibility criteria in the emergency department. The neurosurgical intensive care unit of our center annually receives 100–150 patients with aSAH. Over twelve months, 30 eligible patients will be enrolled in our trial.

The recruited patient who met the criteria will sign and date the institutional informed consent form of the Mashhad University of Medical Sciences before allocating to each group and before initiation of any procedures related to the clinical investigation are performed. Then, required data will be gathered in specific datasheets, including demographic data (name, age, gender, address, and phone number), past medical history including cardiovascular, kidney, and liver diseases, previous episode of SAH, drug history including long term and recent use of any NSAIDs, anti-platelet medications and sensitivity to aspirin or any NSAIDs. Two nurses of the hospital’s intensive care unit will fill case report forms (CRFs) and gather these data. In the absence of exclusion criteria, a file will be specified to each patient that contains a registration form, consent form, diagnostic form, and a 3-months follow-up evaluation sheet.

CRFs will be kept in a file that assigns to each patient. The research coordinator enters data from forms to a data management tool. Only the research coordinator has access to data in a password-protected spreadsheet till the study will be terminated. After this period, the research coordinator will send the spreadsheet to the method center located in the hospital. Also, to assess the patients’ disability, a 3-months follow-up will be accomplished via a phone call or a clinic visit by two independent neurosurgery residents.

Participants who are unable to complete the protocol due to death, clinical complication, or being discharged for any reason will not be excluded from the study. The statisticians will apply the intention to treat analysis.
SDC, part 3. Criteria for the evaluation of vasospasm and disability

Chronic vasospasm can occur clinically with signs and symptoms or non-clinically that would be diagnosed by imaging. In this study, we defined clinical vasospasm as delayed cerebral ischemia (DCI) and diagnosed non-clinically by Transcranial Doppler (TCD). Acceptable definitions for DCI were the development of new, focal neurological deficits, and/or a decreased level of consciousness of at least two points on the Glasgow Coma Scale after other possible causes of deterioration have been excluded or a new infarct revealed by follow-up brain computed tomography, or increases at least two scores of the National Institutes of Health Stroke Scale (NIHSS); in this condition, vasospasm will be confirmed by TCD.

The flow velocity of the middle cerebral artery (MCA) and the basilar artery is measured by TCD at the admission, then every two days. The timeline of the interventions is depicted in figure 3. In MCA, the flow velocity between 120-149 cm/s and Lindegaard ratio 3 to 6 was considered as mild vasospasm (25% vessel obstruction), velocity between 150-199 cm/s and Lindegaard ratio 3 to 6 as moderate vasospasm (50% obstruction) and a velocity more than or equal to 200 cm/s and a Lindegaard ratio greater than 6 as severe vasospasm (more than 50% occlusion). In the basilar artery, the flow velocity between 70-85 cm/s and Lindegaard ratio 2 to 2.49 was considered as mild vasospasm (25% vessel obstruction), the velocity greater than 85 cm/s, and Lindegaard ratio between 2.5 to 2.99 as moderate vasospasm (50% obstruction) and a velocity over 85 cm/s and the Lindegaard ratio greater than or equal to 3 as severe vasospasm (more than 50% obstruction).

Disability will be assessed at discharge and three months after discharge based on the Modified Rankin Scale (mRS). Favorable mRS outcomes are (mRS 1 and 2), and unfavorable outcomes are (mRS 3 to 6).

SDC, part 4. Blinding

Participants of both groups will be blinded to take their correspondent medication or placebo. Also, ibuprofen and placebo will be packed in identical capsules, and they are not distinguishable by participants or study personnel.

The clinical team, including neurosurgeons, radiologists and, ICU department staff, and the neurologist who does TCD, are not aware of which group patients belong to. Outcomes will be
recorded in a list based on patient allocation to either group A or B. Likewise, the statistician would not be aware of what data belongs to either the intervention or placebo groups in the final datasheet. Breaking of the treatment codes will be carried out three months after the inclusion of the last eligible patient. All outcome assessments will be performed before the treatment codes are broken.

**SDC, part 5. Adverse events definition**

Oral administration of ibuprofen has some common adverse reactions that their prevalence is ranged between 1-10%. In these conditions, it is not necessary to discontinue drug consumption. Edema due to fluid retention occurs in 1 to 3%. Central nervous system reactions included dizziness (3-9%), headache (1-3%), and nervousness (1-3%). Skin rashes (3-9%) and pruritus (1-3%) are dermatologic reactions that may occur by ibuprofen consumption. There are some adverse events in the gastrointestinal system which may arise from ibuprofen, including epigastric pain (3-9%), heartburn (3-9%), nausea (3-9%), abdominal pain (1-3%), constipation (1-3%), decreased appetite (1-3%), diarrhea (1-3%), dyspepsia (1-3%), vomiting (1-3%). Tinnitus is the otic complications which may happen by the prevalence of 3-9% 6.

**SDC, part 6. Serious adverse events**

The first possible serious adverse events are cardiovascular thrombotic events, including myocardial infarction (MI). Another serious cardiovascular event is new-onset hypertension or exacerbation of hypertension 7. We will strictly monitor blood pressure as a part of our routine management in the ICU, which helps us detect this event before its remarkable increment.

In general, using the lowest effective dose for the shortest duration of time might reduce the risk of cardiovascular events. In our study, these conditions are considered. In case of any clinical suspicion for MI, in the initial assessment phase, a 12-lead ECG, an abbreviated history, and physical examination will obtain within 10 minutes 8. Then, the serum level of Troponin-I will be measured, and cardiology consultation will be requested for further evaluation or possible therapeutic interventions.

Gastrointestinal events, including an increased risk of ulceration, bleeding, and perforation, are the second possible serious adverse events. Elderly patients and patients with a history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events 9. We avoid enrolling
patients with a history of acute GI bleeding. Concomitant gastro-protective therapy (e.g., proton pump inhibitors (PPIs)) is recommended; as mentioned in the safety section, we use PPIs for all study participants. For the initial evaluation of the patient with the signs of active upper GI bleeding, hemodynamic stability, and the necessity for fluid resuscitation will be assessed. Intravenous pantoprazole at the dose of 40 mg twice daily will be initiated for these patients. Endoscopy within 24 hours of presentation for the diagnosis and treatment of active upper GI bleeding will be accomplished.

The third serious adverse event secondary to ibuprofen use is the accentuation of existing renal dysfunction that is dose-dependent. The proposed criteria for acute kidney injury include an increase in serum creatinine by ≥0.3 mg/dL within 48 hours or an increase to ≥1.5 times the presumed baseline value that is known to have occurred within the last seven days or a decrease in urine volume to <3 mL/kg over six hours. The diagnosis of hemodynamically mediated AKI associated with NSAIDs is suggested by recent NSAID use, the absence of significant proteinuria (<500 mg/day), hematuria, and the bland urine sediment. Among patients with AKI, generally, a renal ultrasound will be done to exclude possible obstruction. In general, the diagnosis is made when kidney function recovery occurs after the NSAID is discontinued. For the treatment of NSAID-induced AKI, the NSAID should be stopped immediately, volume resuscitation will be provided in states of hypovolemia and continued based on a reassessment of volume status including blood pressure/pulse and urine output.

The fourth serious adverse event is anaphylactic reactions. The most common signs and symptoms are cutaneous (e.g. sudden onset of generalized urticarial, angioedema, flushing, and pruritus). Airway will be assessed at first. Epinephrine will be given 0.3 to 0.5 mg intramuscularly (IM), which can be repeated every 5 to 15 minutes. Oxygen will be given 8-10 L/min via face mask as needed. Hypotension, if occurs, will be managed via rapid infusion of 1 to 2 liters intravenously. Adjunctive therapies including IV diphenhydramine 25 to 50 mg, IV ranitidine 50 mg, IV methylprednisolone 125 mg, and monitoring hemodynamic, pulse oximetry, and urine output will be considered as appropriate.

Unanticipated problems resulting in risk to participant or others
Any incident, experience, or outcome that meets the following criteria:
• Unexpected in nature, severity, or frequency (e.g., not described in study-related documents such as the ethics-approved protocol or consent form, etc.).
• Related or possibly related to participation in the research (i.e., possibly related means there is a reasonable possibility that the incident experience or outcome may have been caused by the procedures involved in the research), and suggests that the research places participants or others at greater risk of harm (including physical, psychological, economic, or social harm)

SDC, part 7. Adverse Event (AE) Reporting
The clinical site (ICU nurse and neurosurgery resident) is responsible for reporting AEs to the Methods Centre promptly. Significant new information on ongoing AEs should also be provided promptly to the Methods Centre via the data capture system. Unanticipated problems resulting in risk to participants or others are also to be reported promptly to the Methods Centre.

SDC, part 8. References for supplementary text
1. Chaichana KL, Pradilla G, Huang J, et al. Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage. *World Neurosurg* 2010;73(1):22-41. doi: 10.1016/j.surneu.2009.05.027 [published Online First: 2010/05/11]
2. Vergouwen MD, Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid H. Vasospasm versus delayed cerebral ischemia as an outcome event in clinical trials and observational studies. *Neurocrit Care* 2011;15(2):308-11. doi: 10.1007/s12028-011-9586-8
3. Vergouwen MDI, Vermeulen M, Gijn Jv, et al. Definition of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage as an Outcome Event in Clinical Trials and Observational Studies. *Stroke* 2010;41(10):2391-95. doi: 10.1161/STROKEAHA.110.589275
4. Nassiri F, Ibrahim GM, Badhiwala JH, et al. A Propensity Score-Matched Study of the Use of Non-steroidal Anti-inflammatory Agents Following Aneurysmal Subarachnoid
Hemorrhage. *Neurocrit Care* 2016;25(3):351-58. doi: 10.1007/s12028-016-0266-6 [published Online First: 2016/03/24]

5. Viski S, Olah L. Use of Transcranial Doppler in Intensive Care Unit. *J Crit Care Med (Targu Mures)* 2017;3(3):99-104. doi: 10.1515/jccm-2017-0021 [published Online First: 2018/07/04]

6. Ibuprofen: Drug information. UpToDate2017.

7. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs—differences and similarities. *New England Journal of Medicine* 1991;324(24):1716-25.

8. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Circulation* 2012;126(16):2020-35.

9. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Journal of the American College of Cardiology* 2008;52(18):1502-17.

10. Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. *American Journal of Kidney Diseases* 2005;45(3):531-39.

11. Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. *JAMA internal medicine* 2014;174(11):1755-62.

12. Marmo R, Rotondano G, Piscopo R, et al. Dual therapy versus monotherapy in the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials. *The American journal of gastroenterology* 2007;102(2):279.

13. Shiba M, Suzuki H, Fujimoto M, et al. Role of platelet-derived growth factor in cerebral vasospasm after subarachnoid hemorrhage in rats. *Acta Neurochir Suppl* 2013;115:219-23. doi: 10.1007/978-3-7091-1192-5_40 [published Online First: 2012/08/15]

14. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *Journal of the American Society of Nephrology* 2005;16(11):3365-70.

15. Whelton A, Stout RL, Spilman PS, et al. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure: a prospective, randomized, crossover comparison. *Annals of Internal Medicine* 1990;112(8):568-76.

16. Luciano R. NSAIDs: Acute kidney injury (acute renal failure). In: Palevsky PM, Sheridan A, eds. UpToDate2017.

17. Bock SA, Muñoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. *Journal of Allergy and Clinical Immunology* 2007;119(4):1016.

18. Simons FER, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. *Journal of Allergy and Clinical Immunology* 2001;108(5):871-73.

19. Pumphrey RS. Fatal posture in anaphylactic shock. *Journal of Allergy and Clinical Immunology* 2003;112(2):451-52.

20. Simons KJ, Simons FER. Epinephrine and its use in anaphylaxis: current issues. *Current opinion in allergy and clinical immunology* 2010;10(4):354-61.
